logo
Plus   Neg
Share
Email

Merck: CHMP Supports KEYTRUDA Plus Inlyta To Treat Advanced Renal Cell Carcinoma

Merck (MRK) said CHMP, the Committee of the European Medicines Agency, has recommended approval of KEYTRUDA plus Inlyta combination for the first-line treatment of patients with advanced renal cell carcinoma. The final decision by the European Commission is anticipated in the third quarter of 2019.

The CHMP recommendation is based on the results from the Phase 3 KEYNOTE-426 trial, which showed significant improvements in overall survival, progression-free survival and objective response rate for KEYTRUDA in combination with axitinib compared to sunitinib.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
British luxury car giant Aston Martin unveiled its first SUV at an event in Los Angeles and at a simultaneous event in Beijing. The DBX SUV comes with an aluminium body with a typical Aston Martin grille flanked by LED headlights with LED DRLs. "I can't emphasize enough how incredibly exciting... Google has rolled out an audio news service for Google Assistant, called 'Your News Update,' which will read out a user's customized news feed. According to the tech giant, 'Your News Update' is a smarter way to listen to the news hosted by the Google Assistant. The customized news feed will deliver stories from a variety of media partners, including CBS, Politico, Fox News and CNN. The U.S. Securities and Exchange Commission said it has filed an emergency action and received a temporary restraining order and asset freeze against two Florida residents as well as the two companies controlled by them for an alleged $6 million Ponzi scheme. The Ponzi scheme by Neil Burkholz of Boca Raton, Florida, and Frank Bianco of Pembroke Pines, Florida, defrauded at least 55 investors.
Follow RTT
>